Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution...
Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse
About this item
Full title
Author / Creator
Publisher
Oxford, UK: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
Oxford, UK: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Primary nonresponse and primary nonremission are important limitations of tumor necrosis factor (TNF) antagonists, occurring in 10% to 40% and 50% to 80% of patients with inflammatory bowel disease, respectively. The magnitude of primary nonresponse differs between phase III clinical trials and cohort studies, indicating differences, e.g., in defin...
Alternative Titles
Full title
Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD: Evolution in the Definition and Management of Primary Nonresponse
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1712769083
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1712769083
Other Identifiers
ISSN
1078-0998
E-ISSN
1536-4844
DOI
10.1097/MIB.0000000000000202
